Impact Factor 4.019

The world's most-cited Microbiology journal

Mini Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Microbiol. | doi: 10.3389/fmicb.2018.01682

The Role of Lipoproteins in Mycoplasma-Mediated Immunomodulation

Alexei Christodoulides1, Neha Gupta1, Vahe Yacoubian1, Neil Maithel1, Jordan Parker1 and  Theodoros Kelesidis1*
  • 1Medicine/Infectious Diseases, University of California, Los Angeles, United States

Mycoplasma infections, such as walking pneumonia or pelvic inflammatory diseases, are a major threat to public health. Despite their relatively small physical and genomic size, mycoplasmas are known to elicit strong host immune responses, generally inflammatory, while also being able to evade the immune system. The mycoplasma membrane is composed of approximately two-thirds protein and one-third lipid and contains several lipoproteins that are known to regulate host immune responses. Herein, the immunomodulatory effects of mycoplasma lipoproteins are reviewed. A better understanding of the immunomodulatory effects, both activating and evasive, of Mycoplasma surface lipoproteins will contribute to understanding mechanisms potentially relevant to mycoplasma disease vaccine development and treatment.

Keywords: Mycoplasma, Lipoproteins, Immune System, Immune Modulation, Inflammation

Received: 22 Oct 2017; Accepted: 05 Jul 2018.

Edited by:

Amy Rasley, Lawrence Livermore National Laboratory, United States Department of Energy (DOE), United States

Reviewed by:

Hridayesh Prakash, All India Institute of Medical Sciences, India
M. Victoria Delpino, CONICET Instituto de Inmunología, Genética y Metabolismo (INIGEM), Argentina  

Copyright: © 2018 Christodoulides, Gupta, Yacoubian, Maithel, Parker and Kelesidis. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Theodoros Kelesidis, University of California, Los Angeles, Medicine/Infectious Diseases, Los Angeles, CA, United States, tkelesidis@mednet.ucla.edu